Medical Necessity Determination and Appeal Overturn Policy for Off-Label Use of Farxiga (Dapagliflozin) in Pediatric Members with Heart Failure and Complex Cardiac Conditions
Customize your policy alerts
Sign up for all parklandcommunityhealthplan policy alerts
Know when parklandcommunityhealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs medical-necessity determinations and appeal overturns for off-label dapagliflozin (Farxiga) in members younger than 18 years with heart failure and complex cardiac conditions enrolled in STAR and CHIP benefit plans.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.